MSKCC Clinical Oncology Research Career Development Program

MSKCC 临床肿瘤学研究职业发展计划

• 批准号: 7247892
• 负责人: GARY K SCHWARTZ
• 金额: $ 80.94万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-19 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7247892
• 关键词: Arts; Award; Basic Cancer Research; Basic Science; Biological; Cancer Biology; Caring; Clinical; Clinical Investigator; Clinical Oncology; Clinical Oncology Supplement (K12); Clinical Research; Clinical Research Curriculum Award; Clinical Trials; Clinical Trials Design; Development; Discipline; Doctor of Philosophy; Education; Educational Curriculum; End Point; Environment; Ethics; Faculty; Foundations; Funding; Future; Goals; Grant; Healthcare Systems; Institution; Laboratories; Laboratory Research; Malignant Neoplasms; Medical; Medicine; Memorial Sloan-Kettering Cancer Center; Mentored Clinical Scientist Development Program; Mentors; Methodology; Molecular and Cellular Biology; New York; One-Step dentin bonding system; Operative Surgical Procedures; Pediatric Oncology; Physicians; Process; Protocols documentation; Public Health; Qualifying; Records; Regulation; Reporting; Research; Research Personnel; Research Training; Resources; SECTM1 gene; Schools; Science; Scientist; Students; Testing; Therapeutic; Therapeutic Human Experimentation; Time; Training; Training Programs; Translating; Translational Research; Translations; Writing; anticancer research; base; career; clinical application; concept; data management; design; human disease; human subject; innovation; insight; oncology; patient oriented; patient oriented research; post-doctoral training; programs; response

DESCRIPTION (provided by applicant): In this era of revolutionary insights into the basic scientific principles underlying human diseases, there is continuing concern that advances in biomedical sciences do not translate directly into advances in public health care. In the last decade, the clinical research environment has been challenged by multiple factors including lack of translational research in clinical trials, fragmented oversight of clinical research, funding limitations in the health care system, and a shortage of qualified investigators. Outstanding and comprehensive clinical research training of future clinical investigators with a foundation in basic sciences must be an essential component of this process. This application by Memorial Sloan- Kettering Cancer Center (MSKCC) for the Paul Calabresi Award for Clinical Oncology (K12) brings this institution one step closer to achieving this goal of providing comprehensive training in the design, conduct and ethics of state-of-the-art clinical research for highly motivated trainees (both MDs and PhDs) dedicated to academic careers. We believe this is possible because of two key developments. The first is the successful recompetition of the K30 program which forms a critical part of the clinical oncology training program at MSKCC. The second is the establishment of the Louis V. Gerstner, Jr. Graduate School of Biomedical Science which will allow the awarding of PhDs in Cancer Biology for the first time at MSKCC. This comprehensive research training environment at MSKCC now provides the opportunity to achieve the goals of the K12: the successful career development of both MDs and PhDs in clinical cancer medicine utilizing a firm foundation in laboratory research to reach out and establish clinical trials programs. Trainees eligible for this grant are defined as future investigators in patient-oriented research. The principal aim of the K12 is to provide comprehensive training in the design, conduct and ethics of state-of-the-art clinical research for highly motivated trainees dedicated to academic careers. This program will provide the trainee the ability to: 1. Perform clinical therapeutic research that develops and tests scientific hypotheses based on fundamental and clinical research findings; 2. Design and conduct hypothesis-based, clinical therapeutic protocols which prospectively evaluate both clinical and relevant biological endpoints; 3. Conduct cancer therapeutic research in a team setting in which basic and clinical scientists collaborate and interact to expedite the translation of basic research into patient-oriented therapeutic cancer research.

描述（由申请人提供）：在这个对人类疾病背后的基本科学原理有革命性见解的时代，人们一直担心生物医学科学的进步不能直接转化为公共卫生保健的进步。在过去的十年中，临床研究环境受到多种因素的挑战，包括临床试验中缺乏转化研究，临床研究的分散监督，卫生保健系统的资金限制以及合格研究者的短缺。对具有基础科学基础的未来临床研究人员进行杰出和全面的临床研究培训必须是这一进程的重要组成部分。纪念斯隆-凯特琳癌症中心（MSKCC）申请保罗·卡拉布雷西临床肿瘤学奖（K12）的申请使该机构更接近于实现这一目标，即为致力于学术事业的高度积极的学员（医学博士和博士）提供最先进临床研究的设计、实施和道德方面的全面培训。我们相信这是可能的，因为两个关键的发展。首先是K30项目的成功再竞争，这是MSKCC临床肿瘤学培训项目的关键部分。第二项是建立路易斯·v·郭士纳生物医学科学研究生院，这将允许MSKCC首次授予癌症生物学博士学位。MSKCC的综合研究培训环境现在为实现K12的目标提供了机会：临床癌症医学博士和博士的成功职业发展，利用实验室研究的坚实基础，伸出手来建立临床试验项目。有资格获得这项资助的学员被定义为面向患者的研究的未来研究者。K12的主要目标是为致力于学术事业的高度积极的学员提供最先进临床研究的设计，实施和道德方面的全面培训。该项目将为学员提供以下能力：